HFNC Treatment in COVID-19 Pneumonia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04424836|
Recruitment Status : Completed
First Posted : June 11, 2020
Last Update Posted : July 16, 2020
|Condition or disease||Intervention/treatment|
|Coronavirus Infection Pneumonia, Viral Acute Respiratory Failure||Device: high flow nasal cannula device|
In the first group (group H), the data of patients undergoing HFNC treatment, and in group II (Group K), the data of patients who received COT with a reservoir mask were included.
In HFNC support, the current air temperature is 31-37 degrees, the flow rate is 30-60 lt / min, and the FiO2 value is targeted so that saturation is 93% and above. Initially, continuous treatment was applied intermittently after the partial oxygen pressure / fraction of inspired oxygen(fio2) ratio exceeded 250 and clinical well-being occurred.
In patients in Group K, fingertip saturation was targeted as 93% and above, and a COT was applied with a reservoir mask with a flow rate of 6-15 l / min.
The flow rate was calculated using the formula of FiO2 (%) = 21 + 4 * (liters / min) in patients undergoing COT. Noninvasive mechanical ventilation was applied to patients who could not be provided with adequate clinical and laboratory well-being in both groups (partial oxygen pressure / fraction of inspired oxygen ratio below 150) and invasive mechanical ventilation if this was insufficient.
|Study Type :||Observational|
|Actual Enrollment :||43 participants|
|Official Title:||the Effect of HFNC Treatment on Mortality and Length of ICU Stay in Patient With COVID-19 Pneumonia|
|Actual Study Start Date :||May 15, 2020|
|Actual Primary Completion Date :||June 4, 2020|
|Actual Study Completion Date :||June 5, 2020|
patients get the oxygen supply with high flow nasal cannula . In group H, HFNC device settings the initial flow rate was 30 L/min and could be increased to 60. The Fio2 was adjusted to maintain oxygen saturation as indicated by a pulse oximetry reading of grater than or equal to %90.
Device: high flow nasal cannula device
device is supplying oxygen with heated and humidified air in a high flow rate
patients get the oxygen supply with conventional methods. In group C 6-15 L/min oxygen delivered to patients by conventional methods and targeted to maintain the oxygen saturation %90 or over.
- short term mortality [ Time Frame: in 28 days. ]the mortality rate of patients
- icu stay [ Time Frame: up to 28 days ]means the stay day of patients in intensive care unit
- blood gases [ Time Frame: at the admission time and 24th hour ]partial oxygen pressure, partial carbon dioxide pressure . both measured in mmhg
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04424836
|Sisli Etfal Research and Training Hospital|
|Istanbul, Turkey, 34371|
|Study Chair:||ayse su cinar|